Andros

Andros Pharmaceuticals is a Taiwan-based biopharmaceutical company specializing in the development of novel drug delivery systems and improved new drugs (super generics). The company's core technology includes the S4 localized high-concentration drug delivery system and lipid encapsulation platforms, which enhance the efficacy and safety of topical and transdermal medications. Its clinical pipeline is primarily focused on pain management and skin inflammatory diseases, with lead candidates APC101 (a lidocaine spray for post-herpetic neuralgia) and APC201 (a topical foam for osteoarthritis pain) in mid-to-late-stage clinical development. Andros operates an in-house PIC/S GMP-certified manufacturing facility, supporting its transition from a research-oriented firm to a fully integrated pharmaceutical company. The company actively seeks international partnerships for the commercialization of its proprietary delivery technologies and clinical assets.